# Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).

> **NCT03742349** · PHASE1 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 64 (actual)

## Conditions studied

- Triple Negative Breast Cancer (TNBC)

## Interventions

- **BIOLOGICAL:** spartalizumab
- **BIOLOGICAL:** LAG525
- **DRUG:** NIR178
- **DRUG:** capmatinib
- **BIOLOGICAL:** MCS110
- **BIOLOGICAL:** canakinumab

## Key facts

- **NCT ID:** NCT03742349
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-01-31
- **Primary completion:** 2023-02-06
- **Final completion:** 2023-02-06
- **Target enrollment:** 64 (ACTUAL)
- **Why stopped:** This was a sponsor decision and was not a consequence of any safety concern
- **Last updated:** 2025-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03742349

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03742349, "Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03742349. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*